Abstract
BackgroundSeveral studies seek biological markers that give diagnostic and degree of tumor development. The aim of this study was to validate the determination of plasma DNA using nanotechnology (Nanovue™-NV) in samples of 80 patients with prostate cancer.MethodsBlood samples of 80 patients of the Urology Ambulatory of Faculdade de Medicina do ABC with prostate cancer confirmed by anatomical-pathology criteria were analyzed. DNA extraction was performed using a GFX TM kit (Amersham Pharmacia Biotech, Inc, USA) following the adapted protocol. Plasma was subjected to centrifugation.ResultsThere was a big difference between the first and the second value obtained by NanoVue Only two samples had no differences between duplicates. Maximum difference between duplicates was 38 μg/mL. Average variation between 51 samples was 10.29 μg/mL, although 21 samples had differences above this average. No correlation was observed between pDNA obtained by traditional spectrophotometry and by nanotechnology.ConclusionDetermination of plasma DNA by nanotechnology was not reproducible.
Highlights
A tumor is usually used as a synonym for a neoplasm impairment that may or may not be formed by an abnormal growth of neoplastic cells that appears enlarged in extent
Blood samples of 80 patients of the Urology Ambulatory of Faculdade de Medicina do ABC with prostate cancer confirmed by anatomical-pathology criteria were analyzed
Plasma DNA assessment had been made in duplicate to ensure reliability, there was a big difference between the first and the second value obtained by NanoVue (Table 1)
Summary
A tumor is usually used as a synonym for a neoplasm impairment that may or may not be formed by an abnormal growth of neoplastic cells that appears enlarged in extent. While cancer is by definition malignant, a tumor can be benign, pre-malignant, or malignant, or can represent a lesion without any cancerous potential whatsoever [1,2,3]. Prostate Cancer (PC) or prostatic adenocarcinoma is a malignancy affecting thousands of people worldwide. PC is the sixth most common cancer and the most prevalent in men [4]. Laboratório de Análises Clínicas, Faculdade de Medicina do ABC, Av. Several studies seek biological markers that give diagnostic and degree of tumor development. The aim of this study was to validate the determination of plasma DNA using nanotechnology (NanovueTM-NV) in samples of 80 patients with prostate cancer
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
